EYLEA 40 mg/ml Solution for injection (2024)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Eylea 40 mg/ml solution for injection in a vial.
Qualitative and quantitative composition
1 mL solution for injection contains 40 mg aflibercept*. One vial contains an extractable volume of at least 0.1 mL, equivalent to at least 4 mg aflibercept. This provides a usable amount to deliver a ...
Pharmaceutical form
Solution for injection (injection). The solution is a clear, colourless to pale yellow and iso-osmotic solution.
Therapeutic indications
Eylea is indicated for adults for the treatment of: neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion ...
Posology and method of administration
Eylea is for intravitreal injection only. Eylea must only be administered by a qualified physician experienced in administering intravitreal injections. Posology wet AMD The recommended dose for Eylea ...
Contraindications
Hypersensitivity to the active substance aflibercept or to any of the excipients listed in section 6.1. Active or suspected ocular or periocular infection. Active severe intraocular inflammation.
Special warnings and precautions for use
Traceability In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Intravitreal injection-related ...
Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed. Adjunctive use of verteporfin photodynamic therapy (PDT) and Eylea has not been studied, therefore, a safety profile is not established.
Fertility, pregnancy and lactation
Women of childbearing potential Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of aflibercept (see ...
Effects on ability to drive and use machines
Injection with Eylea has a minor influence on the ability to drive and use machines due to possible temporary visual disturbances associated either with the injection or the eye examination. Patients should ...
Undesirable effects
Summary of the safety profile A total of 3,102 patients constituted the safety population in the eight phase III studies. Among those, 2,501 patients were treated with the recommended dose of 2 mg. Serious ...
Overdose
In clinical trials, doses of up to 4 mg in monthly intervals have been used and isolated cases of overdoses with 8 mg occurred. Overdosing with increased injection volume may increase intraocular pressure. ...
Pharmacodynamic properties
<b>Pharmacotherapeutic group:</b> Ophthalmologicals/Antineovascularisation agents <b>ATC code:</b> S01LA05 Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptor 1 and ...
Pharmacokinetic properties
Eylea is administered directly into the vitreous to exert local effects in the eye. Absorption/Distribution Aflibercept is slowly absorbed from the eye into the systemic circulation after intravitreal ...
Preclinical safety data
Effects in non-clinical studies on repeated dose toxicity were observed only at systemic exposures considered substantially in excess of the maximum human exposure after intravitreal administration at ...
List of excipients
Polysorbate 20 Sodium dihydrogen phosphate, monohydrate (for pH adjustment) Disodium hydrogen phosphate, heptahydrate (for pH adjustment) Sodium chloride Sucrose Water for injection
Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Shelf life
2 years.
Special precautions for storage
Store in a refrigerator (2°C to 8°C). Do not freeze. Store in the original package in order to protect from light. The unopened vial may be stored outside the refrigerator below 25°C for up to 24 hours. ...
Nature and contents of container
Solution in a vial (type I glass) with a stopper (elastomeric rubber), and an 18 G filter needle. Each vial contains an extractable volume of at least 0.1 mL. Pack size of 1 vial + 1 filter needle.
Special precautions for disposal and other handling
The vial is for single use in one eye only. The vial contains more than the recommended dose of 2 mg aflibercept (equivalent to 0.05 mL). The excess volume must be discarded prior to administration. The ...
Marketing authorization holder
Bayer AG, 51368, Leverkusen, Germany
Marketing authorization number(s)
EU/1/12/797/002
Date of first authorization / renewal of the authorization
Date of first authorisation: 22 November 2012 Date of latest renewal: 13 July 2017
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
